ClinicalTrials.gg
CompletedNCT00175929Updated Apr 13, 2015

A Study of Brivaracetam in Subjects With Partial Onset Seizures

A Phase 2 interventional study of Placebo and Brivaracetam in Epilepsy, Focal, sponsored by UCB Pharma. Completed at 57 sites in 9 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-13.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Epilepsies, Partial by UCB S.A. — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · UCB S.A..

Enrollment
12th of 25
157 · median 154
Started
2005
with 4 others
Phase 2
6 of 29
none open now
Registered
11th of 29
by date

Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2005, is one of 6 in phase 2, and was the 11th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 29 studies in Epilepsies, Partial by UCB S.A. is open now. The open studies under Epilepsies, Partial, anywhere →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Epilepsies, Partial by UCB S.A. as a file.
02

Study summary

This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy

03

Conditions studied

  • Epilepsy, Focal

Keywords

  • Epilepsy
  • Focal Epilepsy
  • Partial Onset Seizures
  • Brivaracetam
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
  • Subjects with a history of partial onset seizures
  • Subjects having at least 4 partial onset seizures during the Baseline period and at least 2 partial onset seizures per month during the 3 months preceding Visit 1
  • Subjects being uncontrolled while treated by 1 or 2 concomitant Antiepileptic drug(s) AED(s) being stable
  • Male/ female subjects from 16 to 65 years, both inclusive. Subjects under 18 years may only be included where legally permitted and ethically accepted

Exclusion criteria

Exclusion Criteria:

  • Seizure type IA non-motor as only seizure type
  • History or presence of seizures occurring only in clustered patterns
  • History of cerebrovascular accident (CVA)
  • Presence of any sign suggesting rapidly progressing brain disorder or brain tumor
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo tablets administered twice a day

    Other: Placebo

  • Experimental
    Brivaracetam 50 mg/day

    Brivaracetam 50 mg/day, 25 mg administered twice a day

    Drug: Brivaracetam

  • Experimental
    Brivaracetam 150 mg/day

    Brivaracetam 150 mg/day, 75 mg administered twice a day

    Drug: Brivaracetam

Interventions

  • OtherPlacebo

    Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

  • Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

  • Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)

06

What researchers measure

Primary outcomes

  1. Partial onset seizure frequency (Type I) per week over the 7-week maintenance period

    Partial onset seizure frequency (Type I) per week over the 7-week maintenance period

    Time frame: 7-week maintenance period

Secondary outcomes

  1. Seizure frequency per week for all seizures (types I+II+III) over the 7-week Maintenance period

    Time frame: During the Maintenance period (approximately 7 weeks)

  2. Percentage of reduction from Baseline in seizure frequency per week for partial onset seizures (type I) over the 7-week Maintenance period

    Time frame: During the Maintenance period (approximately 7 weeks)

  3. Percentage of reduction from Baseline in seizure frequency per week for all seizures (types I+II+III) over the 7-week Maintenance period

    Time frame: During the Maintenance period (approximately 7 weeks)

  4. Responder rate in partial onset seizures (type I) over the 7-week Maintenance period

    A responder was defined as a subject with a ≥ 50% reduction in seizure frequency per week from the Baseline period to the Maintenance period.

    Time frame: During the Maintenance period (approximately 7 weeks)

  5. Response to treatment in partial onset seizures (type I) over the 7-week Maintenance period

    The percentage reduction from Baseline in partial seizure frequency per week over the Maintenance period was grouped in 5 categories: \< -25%, -25% to \< 25%, 25% to \< 75%, 75% to ≤ 100%, and 100%.

    Time frame: During the Maintenance period (approximately 7 weeks)

  6. Percentage of seizure-free subjects over the 7-week Maintenance period

    Time frame: During the Maintenance period (approximately 7 weeks)

  7. Percentage of seizure-free days per 4 weeks over Baseline and Maintenance periods

    Time frame: Baseline through Maintenance period (approximately 11 weeks)

  8. Time to N-th seizure in the Maintenance period

    Time frame: During the Maintenance period (approximately 7 weeks)

07

Study locations

57 sites
  • Brugge, Belgium
  • Brussels, Belgium
  • Duffel, Belgium
  • Edegem, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Beroun, Czech Republic
  • Brno, Czech Republic
  • Ceske Budejovice, Czech Republic
  • Praha 1, Czech Republic
  • Praha 5, Czech Republic
  • Kuopio, Finland
  • Oys (Oulu), Finland
  • Tampere, Finland
  • Angers Cedex 1, France
  • Bethune, France
  • Dijon, France
  • Grenoble Cedex 9, France
  • Lille, France
  • Lyon, France
  • Marseille, France
  • Montpellier Cedex 5, France
  • Nancy, France
  • Paris, France
  • Rennes, France
  • Strasbourg, France
  • Tain L'Hermitage, France
  • Toulouse Cedex 04, France
  • Berlin, Germany
  • Bielefeld, Germany
  • Bonn, Germany
  • Chemnitz, Germany
  • Erlangen, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Freiburg, Germany
  • Kehl, Germany
  • Munchen, Germany
  • Ulm, Germany
  • Heemstede, Netherlands
  • Heeze, Netherlands
  • Gdansk, Poland
  • Katowice, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Madrid, Spain
  • Valencia, Spain
  • Vigo, Spain
  • Bucks, United Kingdom
  • Cambridge, United Kingdom
  • Cardiff, United Kingdom
  • Glasgow, United Kingdom
  • Hartshill, United Kingdom
  • Liverpool, United Kingdom
  • Newcastle, United Kingdom
08

References and documents

Publications

  • Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PubMed 35285519 ↗
  • Ben-Menachem E, Baulac M, Hong SB, Cleveland JM, Reichel C, Schulz AL, Wagener G, Brandt C. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. Epilepsy Res. 2021 Feb;170:106526. doi: 10.1016/j.eplepsyres.2020.106526. Epub 2020 Dec 4. PubMed 33461041 ↗
  • Brandt C, Klein P, Badalamenti V, Gasalla T, Whitesides J. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. Epilepsy Behav. 2020 Feb;103(Pt A):106864. doi: 10.1016/j.yebeh.2019.106864. Epub 2020 Jan 12. PubMed 31937513 ↗
  • Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013 Jan;54(1):89-97. doi: 10.1111/j.1528-1167.2012.03598.x. Epub 2012 Jul 19. PubMed 22813235 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
May 2005
Primary completionActual
Mar 2006
CompletionActual
Mar 2006
Last update
Apr 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00175929
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
May 2005
Primary completion
Mar 2006
Completion
Mar 2006
Last update
Apr 13, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion